Zai Lab's DLL3-targeting ADC (zoci) has demonstrated strong and durable responses with favorable safety profile, advancing into Phase III registrational studies. The collaboration with a major pharmaceutical company validates the drug candidate and provides additional development pathways in SCLC and NECs.
Articles that tag ZLAB but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
